TABLE 3.
Persistent Use of Zoledronic Acid Was Associated With Longer Follow-up Duration*
| Treatment Persistency, d* | Follow-Up Duration, mo |
|---|---|
| Untreated | 8.7 |
| 31–90 | 9.6 |
| 91–180 | 11.5 |
| 181–365 | 14.8 |
| >365 | 22.6 |
Treatment persistency was defined as the absence of a gap >45 days between zoledronic acid treatments.